Behcet’s Syndrome treatment
Aug 19, 2025
Precigen’s PAPZIMEOS Wins Full FDA Approval for Recurrent Respiratory Papillomatosis; Tonix’s Tonmya Becomes First FDA-Approved Fibromyalgia Treatment in Over 15 Years; FDA Extends BLA Review for REGENXBIO’s RGX-121 in MPS II Patients; SystImmune’s Izalontamab Brengitecan (EGFRxHER3 ADC) Gets FDA Breakthrough Designation for EGFR-Mutated NSCLC; Soligenix Granted FDA Orphan Drug Status to SGX945 for Behçet’s Disease Therapy Following Phase II Success
Precigen’s PAPZIMEOS Wins Full FDA Approval for Recurrent Respiratory Papillomatosis Precigen, Inc. announced that the FDA has granted full approval to PAPZIMEOS (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). The decision makes PAPZIMEOS the first and on...
Read More...
Jan 13, 2023
Off-label Therapies Dominating the Behcet’s Syndrome Treatment Market
Behcet’s syndrome is an uncommon multisystem inflammatory ailment marked by ulcers in the mouth and genitalia, different skin lesions, and eye abnormalities. It is linked to several new clinical symptoms, all caused by an underlying vasculitis that affects arteries of all diameters. The HLA-B*5101 allele of HLA-...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
